Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Research & Development (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Research & Development for 13 consecutive years, with $31.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 49.21% to $31.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $108.9 million through Dec 2025, up 18.57% year-over-year, with the annual reading at $108.9 million for FY2025, 18.57% up from the prior year.
  • Research & Development hit $31.0 million in Q4 2025 for Coherus Oncology, up from $27.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $82.9 million in Q1 2022 to a low of $11.5 million in Q1 2021.
  • Historically, Research & Development has averaged $34.0 million across 5 years, with a median of $27.8 million in 2024.
  • Biggest YoY gain for Research & Development was 915.24% in 2021; the steepest drop was 65.26% in 2021.
  • Year by year, Research & Development stood at $50.8 million in 2021, then crashed by 42.83% to $29.0 million in 2022, then fell by 9.14% to $26.4 million in 2023, then dropped by 21.27% to $20.8 million in 2024, then skyrocketed by 49.21% to $31.0 million in 2025.
  • Business Quant data shows Research & Development for CHRS at $31.0 million in Q4 2025, $27.3 million in Q3 2025, and $26.3 million in Q2 2025.